Sha Zhou, Hao Song, Long Fengjiao, Wei Yajun, Chen Shaoyi, Li Ting, Yi Lina, Hu Liyang, Lin Zhong, Xian Jianzhong, Pei Xiaofeng
Department of Thoracic Oncology, The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Spinal Surgery Department, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, China.
Ann Transl Med. 2021 Oct;9(20):1538. doi: 10.21037/atm-21-4526.
The role of caudal-related homeobox 2 (CDX2) in the pathogenesis of non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to investigate the mRNA (message RNA) expression of CDX2 in NSCLC, and to determine its relationship with miR-744 (microRNA744) and its potential as a biomarker of NSCLC.
MiR-744 is overexpressed in A549, H460, and H1299 cell lines. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the mRNA expression. A chromatin immunoprecipitation (ChIP) essay was performed to determine the CDX2 binding sites. We then conducted a luciferase reporter essay to analyze interaction between MiR-744 and 3'UTRs (the 3' untranslated sequences). The migration and Boyden chamber method were used to study cell mobility.
In this study, we found that ectopic CDX2 increased the expression of miR-744, while the attenuation of CDX2 reduced the expression of miR-744 by qRT-PCR. Chromatin immunoprecipitation experiments confirmed that CDX2 directly binds to the promoter of miR-744. The luciferase reporter assay further verified the binding sites of -347 to -358 bp in the most likely promoter like sequence of miR-744. CDX2-induced up-regulation of miR-744 can significantly promote the migration and invasion of NSCLC cells, while overexpression CDX2 is sufficient to rescue the migration and invasion capacity of these cells following knockdown of miR-744.
In summary, our results confirmed for the first time the regulatory mechanism of CDX2 on miR-744 transcription and provided a potential mechanism for CDX2 as an oncogene in lung cancer.
尾型相关同源框2(CDX2)在非小细胞肺癌(NSCLC)发病机制中的作用尚不清楚。本研究旨在调查CDX2在NSCLC中的信使核糖核酸(mRNA)表达,并确定其与微小核糖核酸-744(miR-744)的关系及其作为NSCLC生物标志物的潜力。
miR-744在A549、H460和H1299细胞系中过表达。采用实时定量聚合酶链反应(qRT-PCR)检测mRNA表达。进行染色质免疫沉淀(ChIP)实验以确定CDX2结合位点。然后我们进行荧光素酶报告基因实验以分析miR-744与3'非翻译区(3'UTRs)之间的相互作用。采用迁移实验和博伊登小室法研究细胞迁移能力。
在本研究中,我们发现通过qRT-PCR检测,异位表达的CDX2增加了miR-744的表达,而CDX2表达减弱则降低了miR-744的表达。染色质免疫沉淀实验证实CDX2直接结合miR-744的启动子。荧光素酶报告基因实验进一步验证了在miR-744最可能的启动子样序列中-347至-358 bp的结合位点。CDX2诱导的miR-744上调可显著促进NSCLC细胞的迁移和侵袭,而过表达CDX2足以挽救miR-744敲低后这些细胞的迁移和侵袭能力。
总之,我们的结果首次证实了CDX2对miR-744转录的调控机制,并为CDX2作为肺癌癌基因提供了潜在机制。